Stay updated with breaking news from Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Myovant Sciences Ltd. (NYSE:MYOV – Get Rating) have been given an average recommendation of “Hold” by the seven analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the […]
/PRNewswire/ -- AKI is also associated with long-term risks of Chronic Kidney Disease (CKD), End Stage Kidney Disease (ESKD), and other organ dysfunction in...
Roivant Sciences Ltd (NASDAQ:ROIV – Get Rating) CEO Matthew Gline sold 82,006 shares of the stock in a transaction on Friday, March 18th. The stock was sold at an average price of $5.13, for a total transaction of $420,690.78. The transaction was disclosed in a document filed with the SEC, which is available at this […]
Company plans to uplist to the Nasdaq Capital MarketLONDON and PHOENIX, March 04, 2022 -- AccuStem Sciences, Inc. , a life sciences company dedicated to improving outcomes for patients with cancer,... | March 4, 2022
Investegate announcements from AccuStem Sciences, Inc, AccuStem Sciences, Inc. Appoints New Executive Leadership Team